Invitae, which offers consumers a suite of genetic tests as a single service, announced terms for its IPO on Monday. The San Francisco, CA-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Invitae would command a fully diluted market value of $436 million. <\/p>\n
Invitae, which was founded in 2010 and booked $1 million in sales for the 12 months ended September 30, 2014, plans to list on the NYSE under the symbol NVTA. J.P. Morgan is the sole bookrunner on the deal. It is expected to price during the week of February 9, 2015. <\/p>\n
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.<\/p>\n
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.<\/p>\n
<\/p>\n
Visit link: Invitae, which offers consumers a suite of genetic tests as a single service, announced terms for its IPO on Monday. The San Francisco, CA-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Invitae would command a fully diluted market value of $436 million Continue reading
\nKnow your genome: Invitae sets terms for $75 million IPO<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"